Fractyl Health, Inc.
GUTS is a binary, pre-revenue clinical story with useful near-term data catalysts, but the stock still screens as overdependent on one pivotal readout with runway only into early 2027 and a quant base value of $0.69, slightly below the current $0.70.
Fractyl is easier to understand than to own. The stock is basically a wager on whether Revita's pivotal REMAIN-1 study can convert encouraging midpoint signals into approvable data on time, then make it through a de novo filing path without a financing accident. The clinical signal is real enough to matter. Management said Revita patients maintained more than 80% of prior GLP-1-induced weight loss at one year versus 46% for sham, with zero serious adverse events through one year, and both co-primary endpoints are estimated to be powered above 95%. That is why the stock is not an obvious short even after a long decline.
The problem is that the business underneath the catalyst is still extremely thin. FY2025 revenue is $0.0B, EPS is -$1.86, free cash flow is about -$0.1B, and Q2 adjusted EBITDA was -$16.3M. The balance sheet carries $0.1B of debt and debt/equity of 6.52. Management says runway extends into early 2027 and the ATM is closed, but that still means the company is operating with a short financing fuse if pivotal data, FDA review, or filing timing slips. For a pre-revenue biotech, a few quarters matter a lot.
What the market may still be underestimating is not the science alone, but the gap between good data and a financeable commercial story. Management has not yet disclosed pricing or profitability assumptions, and those details are pushed to a September Investor Day. Even if the early Q4 data hit, investors still need to underwrite reimbursement, procedure adoption, operator training, and whether this niche remains attractive if GLP-1 therapies keep improving persistence and breadth. That future competitive map matters more than any backward-looking multiple, because there is no real earnings base yet.
The reason conviction stops at medium, not high, is that the setup is not one-sided. The stock is already -71.4% from its 52-week high and -95.2% from its 5-year high, so a clearly positive readout could produce a sharp move higher. But at $0.70, with the engine's base value at $0.69, the risk-adjusted setup still skews away from owning ahead of binary data unless an investor has a specific event-driven edge or very high tolerance for dilution and regulatory risk.
Early Q4 data are clearly positive, de novo submission proceeds on time, and the market starts underwriting a real obesity-device launch.
Data path remains intact but investors wait for full pivotal and regulatory clarity, leaving shares near the engine's $0.69 fair value.
Pivotal data disappoints or de novo timing slips, forcing a financing before commercialization and repricing the equity closer to cash-stress levels.
Quant call (HOLD) diverges from analyst consensus (Strong Buy: 2 buy / 0 hold / 0 sell) — resolve explicitly.
The single greatest edge an investor can have is a long-term orientation.
Forward earnings power is still essentially absent, so trailing and forward P/E are not usable and the stock must be valued on probability-adjusted regulatory and commercialization outcomes rather than profits. The moat today is mostly clinical know-how, Breakthrough status, and procedural positioning in GLP-1 weight maintenance, but in 3-5 years that moat only matters if Revita reaches market before drug-based obesity regimens become even more effective and persistent. AI is not a core advantage here, it may help trial operations and patient selection at the margin, but it does not change the biology or the regulatory burden. Regulation matters far more than macro rates for this name, and until de novo clearance probability rises materially, the stock remains a trade on data rather than an investable earnings compounder.
- Early Q4 2026 REMAIN-1 6-month top-line data is the dominant value inflection, with management saying both co-primary endpoints are powered above 95%.
- Liquidity remains tight for a pre-revenue model, with ~$16M Q2 cash used in operations, adjusted EBITDA of -$16.3M, and runway only into early 2027.
- The stock has already reset hard, now -71.4% versus the $2.44 52-week high and 31.0% below the $1.01 200-day average, which limits downside from sentiment alone but does not remove financing and trial risk.
- 1-year REMAIN-1 midpoint data showed Revita maintained more than 80% of prior GLP-1 weight loss versus 46% for sham, a clinically meaningful signal if replicated in the pivotal cohort.
- Operational execution improved in 2026, with >300 participants randomized across >30 sites and >20 operators, retention well above 90%, and three consecutive quarterly EPS beats of +178.9%, +23.5%, and +11.1% versus consensus.
- Regulatory framing got better, with management citing moderate-risk FDA feedback that supports a potential de novo pathway rather than a high-risk classification, and Breakthrough plus CMS pass-through could help reimbursement if cleared.
- Cost discipline is improving after enrollment completion, with Q2 adjusted EBITDA improving $7.7M YoY and Q2 operating cash use of approximately $16M described as the lower post-randomization run rate.
- The business remains pre-revenue, with FY2025 revenue shown as $0.0B, FY2025 EPS -$1.86, operating margin -161246.7%, and net margin -148511.7%, so there is no current earnings power to underwrite.
- Balance-sheet risk is real for a company this small, with $0.1B of total debt, debt/equity of 6.52, and runway only into early 2027, which leaves little margin if pivotal timing or filing slips by even a quarter or two.
- Management's prior timeline has slipped before: in the 2024 Q3 call, Rejuva-001 first-in-human was guided for H1 2025, but current guidance says first patient dosing is only imminent in 2H 2026.
- Commercial visibility is still thin, with management not disclosing pricing or profitability assumptions until the September Investor Day, so even good pivotal data would still leave reimbursement and launch economics underdefined.
| Metric | Value | Context |
|---|---|---|
| Price target | $0.69 | Ground-truth engine target, -1.6% vs current $0.70, low confidence |
| Quant baseline call | HOLD | Low conviction, basis: sales_quality_blend |
| FY2025 revenue | $0.0B | -49.6% YoY, effectively pre-revenue |
| FY2025 EPS | -$1.86 | Loss-making, 50.8% YoY |
| Operating margin | -161246.7% | Worse than prior FY -100571.0%, not meaningful on near-zero revenue |
| Total debt | $0.1B | With debt/equity 6.52, leverage is heavy for a pre-revenue biotech |
| Current ratio | 4.78 | Near-term liquidity exists, but runway still only into early 2027 |
| Free cash flow | -$0.1B | Cash-consuming model, no buybacks or dividends |
| Q2 2026 adjusted EBITDA | -$16.3M | Improved $7.7M YoY after pivotal randomization completion |
| Q2 2026 cash used in operations | ~$16M | Management says this better reflects the post-randomization run rate |
| 52-week position | $0.70 vs $0.38-$2.44 | Shares are -71.4% from the high and -31.0% below the $1.01 200-day average |
The biggest risk is a negative or ambiguous early Q4 2026 REMAIN-1 readout, because with no revenue and runway only into early 2027, one failed catalyst could force a highly dilutive financing.
REMAIN-1 6-month top-line pivotal data in early Q4 2026, followed by a potential late Q4 2026 de novo submission update.
Ownership is concentrated, with the top three institutions holding 46.4%, which can support the stock if data are good but can also amplify volatility around a binary catalyst. Short interest is modest at 2.41% of shares outstanding, though deep-dive data show 3.12M shares short on a 21M float and only 0.5 days-to-cover, so there is not a strong squeeze setup. Options positioning data are not provided, and the low days-to-cover suggests price action will be driven more by trial news than by technical short covering.
Still effectively pre-commercial, with value concentrated in Revita and earlier-stage Rejuva assets rather than reported sales.
REMAIN-1 pivotal is the core asset, with >300 patients randomized and top-line 6-month data due in early Q4 2026.
Rejuva-001 first patient dosing is imminent in 2H 2026, with preliminary data expected in 2H 2026.
Fractyl stayed on track for early Q4 pivotal data while reiterating runway into early 2027.
Execution has improved, but credibility is mixed rather than strong. On the positive side, management now appears to be hitting nearer-term trial operations, with >300 patients randomized, retention well above 90%, and current guidance that "We remain on track to report top-line 6-month primary endpoint data in early Q4 2026 and expect to report top-line 12-month data from the REMAIN-1 pivotal cohort in Q1 2027." The earnings track record also improved sharply in 2026 after misses in 2025-03-03 (-18.2%), 2025-08-12 (-43.2%), and 2025-11-12 (-2.9%), turning into beats of +178.9%, +23.5%, and +11.1%. The miss against the 2024 Q3 roadmap is most visible in Rejuva, where management had guided Rejuva-001 first-in-human initiation in H1 2025, but current guidance only points to first patient dosing in 2H 2026. Cash-runway messaging was directionally credible, moving from $84.7M and runway into Q4 2025 then, to runway into early 2027 now, but the development timeline has clearly stretched.
We remain on track to report top-line 6-month primary endpoint data in early Q4 2026 and expect to report top-line 12-month data from the REMAIN-1 pivotal cohort in Q1 2027.
Our runway extends into early 2027, beyond the pivotal data readout and through a potential de novo submission. Our ATM facility remains closed. We do not plan to raise capital before we have pivotal data in hand.
Revita patients maintained more than 80% of their prior GLP-1-induced weight loss at 1 year, compared with 46% in the sham arm.
Cash used in operations was approximately $16 million in Q2, which is a better reflection of our post-randomization run rate than Q1.
We remain on track for a potential de novo submission in late Q4 2026, following the 6-month pivotal data readout.
The moat is narrow today. Fractyl has differentiated clinical positioning around weight maintenance after GLP-1 discontinuation, plus Breakthrough device status and a procedural approach that could appeal to patients seeking durability without chronic drug exposure. Durability is unproven until pivotal and regulatory success arrive, and over 3-5 years the moat could weaken if obesity drugs improve persistence, pricing, or combination outcomes faster than Revita commercializes.
Capital allocation is survival-focused, not shareholder-return focused. Buybacks and dividends are $0.0B, capex is $0.0B, and free cash flow is negative at roughly -$0.1B, which is appropriate for a development-stage biotech but leaves no flexibility. The positive read is that management says the ATM remains closed and no raise is planned before pivotal data, but that is a timing choice, not proof of balance-sheet strength.
GUTS rates SELL at Medium conviction. The company has a real catalyst path and better operating discipline than it showed in 2025, but the stock still rests on a single pivotal dataset, has no revenue, and carries a financing clock that only runs into early 2027. At $0.70 versus a ground-truth target of $0.69, the risk-adjusted upside is not enough to justify owning ahead of binary data. A change to BUY would require either clearly positive pivotal data with a de-risked FDA path, or a share price that discounts a much harsher financing outcome than the current one.
≣ Full research note tap to expand
Executive Summary
SELL, Medium conviction. Rated SELL, Medium conviction. Fractyl has improved execution in 2026, with three straight EPS beats and a clearer REMAIN-1 timeline, but the business still has no revenue, burns about $16M of operating cash per quarter, and depends on early Q4 2026 pivotal data plus an FDA de novo path that is not yet locked. At $0.70, the setup is better than it was near the highs, but not cheap enough for a binary event-driven biotech whose base case remains $0.69 with low confidence.
Investment Thesis
Fractyl is easier to understand than to own. The stock is basically a wager on whether Revita's pivotal REMAIN-1 study can convert encouraging midpoint signals into approvable data on time, then make it through a de novo filing path without a financing accident. The clinical signal is real enough to matter. Management said Revita patients maintained more than 80% of prior GLP-1-induced weight loss at one year versus 46% for sham, with zero serious adverse events through one year, and both co-primary endpoints are estimated to be powered above 95%. That is why the stock is not an obvious short even after a long decline.
The problem is that the business underneath the catalyst is still extremely thin. FY2025 revenue is $0.0B, EPS is -$1.86, free cash flow is about -$0.1B, and Q2 adjusted EBITDA was -$16.3M. The balance sheet carries $0.1B of debt and debt/equity of 6.52. Management says runway extends into early 2027 and the ATM is closed, but that still means the company is operating with a short financing fuse if pivotal data, FDA review, or filing timing slips. For a pre-revenue biotech, a few quarters matter a lot.
What the market may still be underestimating is not the science alone, but the gap between good data and a financeable commercial story. Management has not yet disclosed pricing or profitability assumptions, and those details are pushed to a September Investor Day. Even if the early Q4 data hit, investors still need to underwrite reimbursement, procedure adoption, operator training, and whether this niche remains attractive if GLP-1 therapies keep improving persistence and breadth. That future competitive map matters more than any backward-looking multiple, because there is no real earnings base yet.
The reason conviction stops at medium, not high, is that the setup is not one-sided. The stock is already -71.4% from its 52-week high and -95.2% from its 5-year high, so a clearly positive readout could produce a sharp move higher. But at $0.70, with the engine's base value at $0.69, the risk-adjusted setup still skews away from owning ahead of binary data unless an investor has a specific event-driven edge or very high tolerance for dilution and regulatory risk.
Key Metrics
| Metric | Value | Context |
|---|---|---|
| Price target | $0.69 | Ground-truth engine target, -1.6% vs current $0.70, low confidence |
| Quant baseline call | HOLD | Low conviction, basis: sales_quality_blend |
| FY2025 revenue | $0.0B | -49.6% YoY, effectively pre-revenue |
| FY2025 EPS | -$1.86 | Loss-making, 50.8% YoY |
| Operating margin | -161246.7% | Worse than prior FY -100571.0%, not meaningful on near-zero revenue |
| Total debt | $0.1B | With debt/equity 6.52, leverage is heavy for a pre-revenue biotech |
| Current ratio | 4.78 | Near-term liquidity exists, but runway still only into early 2027 |
| Free cash flow | -$0.1B | Cash-consuming model, no buybacks or dividends |
| Q2 2026 adjusted EBITDA | -$16.3M | Improved $7.7M YoY after pivotal randomization completion |
| Q2 2026 cash used in operations | ~$16M | Management says this better reflects the post-randomization run rate |
| 52-week position | $0.70 vs $0.38-$2.44 | Shares are -71.4% from the high and -31.0% below the $1.01 200-day average |
Financial Strength
Financial strength is adequate only for the next catalyst window, not robust. The current ratio of 4.78 suggests near-term obligations are covered, but that is offset by a capital structure carrying $0.1B of debt and debt/equity of 6.52 despite no commercial revenue base. Cash burn appears to be improving after pivotal randomization, with Q2 operating cash use around $16M and adjusted EBITDA improving $7.7M YoY, but the company is still a heavy cash consumer with negative free cash flow and a runway that only reaches early 2027. That keeps financing risk front and center if any milestone slips.
Competitive Position
The moat is narrow today. Fractyl has differentiated clinical positioning around weight maintenance after GLP-1 discontinuation, plus Breakthrough device status and a procedural approach that could appeal to patients seeking durability without chronic drug exposure. Durability is unproven until pivotal and regulatory success arrive, and over 3-5 years the moat could weaken if obesity drugs improve persistence, pricing, or combination outcomes faster than Revita commercializes.
Management & Guidance
Current guidance is clear and near-dated: early Q4 2026 for REMAIN-1 6-month top-line data, Q1 2027 for 12-month data, a potential late Q4 2026 de novo submission, Rejuva-001 first patient dosing in 2H 2026, and runway into early 2027. Credibility is improved by better 2026 earnings execution and operational progress across >30 sites, but not spotless because earlier roadmaps slipped, especially the Rejuva-001 first-in-human timing from H1 2025 then to 2H 2026 now. Net, management looks credible on near-term operational delivery but less so on long-range development timing.
Segment Analysis
- Total company ($0.0B revenue in FY2025): Still effectively pre-commercial, with value concentrated in Revita and earlier-stage Rejuva assets rather than reported sales.
- Revita (Primary value driver): REMAIN-1 pivotal is the core asset, with >300 patients randomized and top-line 6-month data due in early Q4 2026.
- Rejuva (Early-stage pipeline, no disclosed revenue): Rejuva-001 first patient dosing is imminent in 2H 2026, with preliminary data expected in 2H 2026.
Capital Allocation
Capital allocation is survival-focused, not shareholder-return focused. Buybacks and dividends are $0.0B, capex is $0.0B, and free cash flow is negative at roughly -$0.1B, which is appropriate for a development-stage biotech but leaves no flexibility. The positive read is that management says the ATM remains closed and no raise is planned before pivotal data, but that is a timing choice, not proof of balance-sheet strength.
Management Execution & Track Record
Execution has improved, but credibility is mixed rather than strong. On the positive side, management now appears to be hitting nearer-term trial operations, with >300 patients randomized, retention well above 90%, and current guidance that "We remain on track to report top-line 6-month primary endpoint data in early Q4 2026 and expect to report top-line 12-month data from the REMAIN-1 pivotal cohort in Q1 2027." The earnings track record also improved sharply in 2026 after misses in 2025-03-03 (-18.2%), 2025-08-12 (-43.2%), and 2025-11-12 (-2.9%), turning into beats of +178.9%, +23.5%, and +11.1%. The miss against the 2024 Q3 roadmap is most visible in Rejuva, where management had guided Rejuva-001 first-in-human initiation in H1 2025, but current guidance only points to first patient dosing in 2H 2026. Cash-runway messaging was directionally credible, moving from $84.7M and runway into Q4 2025 then, to runway into early 2027 now, but the development timeline has clearly stretched.
Positioning & Flows
Ownership is concentrated, with the top three institutions holding 46.4%, which can support the stock if data are good but can also amplify volatility around a binary catalyst. Short interest is modest at 2.41% of shares outstanding, though deep-dive data show 3.12M shares short on a 21M float and only 0.5 days-to-cover, so there is not a strong squeeze setup. Options positioning data are not provided, and the low days-to-cover suggests price action will be driven more by trial news than by technical short covering.
Bull Case
- 1-year REMAIN-1 midpoint data showed Revita maintained more than 80% of prior GLP-1 weight loss versus 46% for sham, a clinically meaningful signal if replicated in the pivotal cohort.
- Operational execution improved in 2026, with >300 participants randomized across >30 sites and >20 operators, retention well above 90%, and three consecutive quarterly EPS beats of +178.9%, +23.5%, and +11.1% versus consensus.
- Regulatory framing got better, with management citing moderate-risk FDA feedback that supports a potential de novo pathway rather than a high-risk classification, and Breakthrough plus CMS pass-through could help reimbursement if cleared.
- Cost discipline is improving after enrollment completion, with Q2 adjusted EBITDA improving $7.7M YoY and Q2 operating cash use of approximately $16M described as the lower post-randomization run rate.
Bear Case
- The business remains pre-revenue, with FY2025 revenue shown as $0.0B, FY2025 EPS -$1.86, operating margin -161246.7%, and net margin -148511.7%, so there is no current earnings power to underwrite.
- Balance-sheet risk is real for a company this small, with $0.1B of total debt, debt/equity of 6.52, and runway only into early 2027, which leaves little margin if pivotal timing or filing slips by even a quarter or two.
- Management's prior timeline has slipped before: in the 2024 Q3 call, Rejuva-001 first-in-human was guided for H1 2025, but current guidance says first patient dosing is only imminent in 2H 2026.
- Commercial visibility is still thin, with management not disclosing pricing or profitability assumptions until the September Investor Day, so even good pivotal data would still leave reimbursement and launch economics underdefined.
Valuation & Price Target
Engine price target $0.69 (-1.6% vs current), Low confidence.
- Quality-adjusted: $0.69 (20% weight)
The quant baseline is HOLD with a $0.69 target and low confidence. The rating diverges to SELL because the stock is not just slightly above fair value at $0.70, it is also exposed to a binary catalyst with no revenue, quarterly operating cash burn of about $16M, and runway only into early 2027, which leaves limited room for trial or filing slippage. The improved 2026 execution and positive midpoint data argue against an aggressive short thesis, but they do not offset the fact that the entire equity still depends on one pivotal dataset and an FDA safety review. Sell-side consensus sits at Strong Buy from just 2 firms, which is too small a sample to outweigh the balance-sheet and event-risk math.
Risk Assessment
Risk score 54/100 (Moderate). The biggest risk is a negative or ambiguous early Q4 2026 REMAIN-1 readout, because with no revenue and runway only into early 2027, one failed catalyst could force a highly dilutive financing.
The Bottom Line
GUTS rates SELL at Medium conviction. The company has a real catalyst path and better operating discipline than it showed in 2025, but the stock still rests on a single pivotal dataset, has no revenue, and carries a financing clock that only runs into early 2027. At $0.70 versus a ground-truth target of $0.69, the risk-adjusted upside is not enough to justify owning ahead of binary data. A change to BUY would require either clearly positive pivotal data with a de-risked FDA path, or a share price that discounts a much harsher financing outcome than the current one.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr